Structural insights into the inhibition of the nsP2 protease from Chikungunya virus by molecular modeling approaches
- PMID: 36097090
- DOI: 10.1007/s00894-022-05316-3
Structural insights into the inhibition of the nsP2 protease from Chikungunya virus by molecular modeling approaches
Abstract
Chikungunya virus (CHIKV) is the etiological agent of the Chikungunya fever which has spread worldwide. Clinically, this disease may lead to prolonged incapacitating joint pain that can compromise remarkably the patients' quality of life. However, there are no licensed vaccines or specific drugs to fight this infection yet, making the search for novel therapies an imperative need. In this scenario, the CHIKV nsP2 protease emerged as an attractive therapeutic target once this protein plays a pivotal role in viral replication and pathogenesis. Hence, we investigated the structural basis for the inhibition of this enzyme by using molecular docking and dynamics simulations. Compounds with inhibitory activities against CHIKV nsP2 protease determined experimentally were selected from the literature. Docking studies with a set of stereoisomers showed that trans isomers, but not cis ones, bound close to the catalytic dyad which may explain isomerism requirements to the enzyme's inhibition. Further, binding mode analyses of other known inhibitors revealed highly conserved contacts between inhibitors and enzyme residues like N1011, C1013, A1046, Y1079, N1082, W1084, L1205, and M1242. Molecular dynamics simulations reinforced the importance of some of these interactions and pointed to nonpolar interactions as the main forces for inhibitors' binding. Finally, we observed that true inhibitors exhibited lower structural fluctuation, higher ligand efficiency and did not induce significant changes in protein correlated motions. Collectively, our findings might allow discerning true inhibitors from false ones and can guide drug development efforts targeting the nsP2 protease to fight CHIKV infections in the future.
Keywords: Alphavirus; Antiviral; Drug design; Molecular modeling; nsP2.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Design, synthesis, antiviral evaluation, and In silico studies of acrylamides targeting nsP2 from Chikungunya virus.Eur J Med Chem. 2023 Oct 5;258:115572. doi: 10.1016/j.ejmech.2023.115572. Epub 2023 Jun 19. Eur J Med Chem. 2023. PMID: 37364511
-
Conformer and pharmacophore based identification of peptidomimetic inhibitors of chikungunya virus nsP2 protease.J Biomol Struct Dyn. 2017 Dec;35(16):3522-3539. doi: 10.1080/07391102.2016.1261046. Epub 2016 Dec 2. J Biomol Struct Dyn. 2017. PMID: 27844505
-
Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of Chikungunya virus nsP2 protease.J Mol Model. 2012 Jan;18(1):39-51. doi: 10.1007/s00894-011-1018-3. Epub 2011 Mar 29. J Mol Model. 2012. PMID: 21445710
-
Recent advances in phytocompounds as potential Chikungunya virus non-structural protein 2 protease antagonists: A systematic review.Phytomedicine. 2025 Jan;136:156359. doi: 10.1016/j.phymed.2024.156359. Epub 2024 Dec 29. Phytomedicine. 2025. PMID: 39756312
-
Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.Curr Comput Aided Drug Des. 2017 Nov 10;13(4):346-361. doi: 10.2174/1573409913666170309145308. Curr Comput Aided Drug Des. 2017. PMID: 28294048 Review.
Cited by
-
In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus.ACS Omega. 2024 Jun 13;9(25):27632-27642. doi: 10.1021/acsomega.4c03417. eCollection 2024 Jun 25. ACS Omega. 2024. PMID: 38947813 Free PMC article.
-
Antiviral evaluation of 1,4-disubstituted-1,2,3-triazole derivatives against Chikungunya virus.Future Virol. 2023 Sep;18(13):865-880. doi: 10.2217/fvl-2023-0142. Epub 2023 Oct 25. Future Virol. 2023. PMID: 37974899 Free PMC article.
References
-
- de Ximenes MdeFFM, de Galvão JMA, Inacio CLS et al (2020) Arbovirus expansion: new species of culicids infected by the Chikungunya virus in an urban park of Brazil. Acta Trop 209:1–5. https://doi.org/10.1016/J.ACTATROPICA.2020.105538 - DOI
-
- Abdelnabi R, Neyts J, Delang L (2017) Chikungunya virus infections: time to act, time to treat. Curr Opin Virol 24:25–30. https://doi.org/10.1016/j.coviro.2017.03.016 - DOI - PubMed
-
- Vairo F, Haider N, Kock R et al (2019) Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention. Infect Dis Clin North Am 33:1003–1025. https://doi.org/10.1016/j.idc.2019.08.006 - DOI - PubMed
-
- ECDC (2022) Chikungunya worldwide overview. https://www.ecdc.europa.eu/en/chikungunya-monthly .
-
- Kraemer MUG, Reiner RC, Brady OJ et al (2019) Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol 4:854–863. https://doi.org/10.1038/s41564-019-0376-y - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical